• Yong Chen, Fangfang Wu, Li Zhang, Li Du, and Xiang Yan.
• The First Hospital of Lanzhou University.
• Medicine (Baltimore). 2020 Nov 6; 99 (45): e23120.

BackgroundMeprin is a member of the astaxanthin family; it performs many functions through a wide range of proteolytic enzyme activities during health and disease, including tumors and inflammatory conditions. The purpose of this systematic review was to evaluate the predictive value of MEP1A in tumor prognosis.MethodsA comprehensive search was conducted on PubMed, Cochrane library, and Web of Science Database using a developed search strategy. The Newcastle-Ottawa Scale (NOS) or the Cochrane Collaboration's tool for assessing risk of bias will be used to access the methodological quality of included studies, and GRADE will be applied to evaluate evidence quality of outcomes. All analyses were performed by Stata 15.0.ResultsThe results will systematically summarize and display the currently collected evidence on the predictive value of MEP1A in different tumor prognosis.ConclusionThis study may play a certain role in predicting the prognosis of cancer patients in the future, and may prompt clinicians to make necessary treatment or prevention plans as soon as possible.Ethics And CommunicationIt is not necessary because the present systematic review is based on published studies.Inplasy Registration NumberINPLASY2020100005.

12 keywords...

hide…